CEOInterviews.AI
Start App
Get an email when Mark Cuban gives a new interview
One email per new interview. Unsubscribe in one click.
Mark Cuban
Co-founder; minority owner, Dallas Mavericks, Cost Plus Drugs

"I'm Not a Doomer!" Mark Cuban Explains Why AI Hackers Can Be Defeated With AI Defense | AC1B

📅 Oct 26, 2026 DRM News 9 MIN 1258 VIEWS 25 SEGMENTS · 2 SPEAKERS
Billionaire entrepreneur Mark Cuban compared AI-powered hacking agents to cockroaches during Reuters Total Health 2026 in Nashville, warning that attackers can deploy countless AI agents to exploit cybersecurity weaknesses. However, Cuban said he remains optimistic, arguing that defensive AI can counter emerging threats. The Cost Plus Drugs co-founder also criticized healthcare pricing and discussed AI-powered pharmaceutical manufacturing. For more details, watch our story and subscribe to our channel, DRM News. "AI Is Like Cockroaches!" Mark Cuban Warns About Hackers but Says They Can Be Sto...

What Mark Cuban said

Written from the verified transcript and checked against it. Every figure links to the moment it was said.

Mark Cuban said that if self-insured employers focused on contract details, the entire US health care system could change without new legislation. He supported single payer but criticized the lack of a concrete plan. On premium tax credits, he said they just funnel money to big carriers and cited that 40% of people can't afford a $400 emergency bill versus a $2,700 average deductible. He proposed two fixes: count out-of-pocket purchases toward deductibles nationally (currently done in eight states) and require all taxpayer-funded contracts to be published unredacted. He said PBMs threatened brand manufacturers to avoid working with Cost Plus Drugs, but publishing low prices for specialty generics like imatinib drove costs down. Cuban detailed his Dallas manufacturing pods that shrink a football-field-sized plant to 5,000 square feet, and then to a trailer, letting it manufacture drugs cheaper than buying from India. He said only FDA ANDA fees ($365,000 per drug) block expansion. On politics, he said no candidate knows what they're doing. On AI, he argued brute-force hacking can be countered by brute-force defense.

Key takeaways

  1. He said PBMs threatened to remove brands from formularies if they worked with CostPlusDrugs.com.
  2. He claimed his Dallas manufacturing pods can make drugs cheaper than importing from India, even while buying higher-priced API.
  3. Cuban said $365,000 ANDA fees per drug, not manufacturing costs, block US reshorting.

Numbers and commitments

FigureWhat it refers toTypeAt
40% Share of people who can't afford a $400 emergency bill metric 1:09
$2,700 Average deductible for a silver plan before premium tax credits removal metric 1:09
70 employees Cost Plus Drugs employee count metric 4:28
15% Markup on specialty generics at Cost Plus Drugs price 4:28
5,000 square feet Size of Dallas manufacturing facility after shrinking from football field metric 5:38
$365,000 Cost per ANDA application price 6:31
$365 million Total ANDA cost for 1,000 new drugs price 6:31
2,500 drugs Number of drugs Cuban wants to manufacture in US metric 6:31

Chapters

  1. 0:00Changing health care without legislation
  2. 1:09Premium tax credits help carriers
  3. 2:04Two proposals for affordability
  4. 2:40Price discovery and contracts
  5. 4:02PBMs blocking Cost Plus Drugs
  6. 4:28Specialty generics price drop
  7. 5:38Dallas manufacturing pods
  8. 6:31FDA ANDA fees hurdle
  9. 7:37Politics and healthcare
  10. 7:56AI defense against hacks

Questions asked in this interview

2
  1. 0:01How come you didn't get a warm welcome?
  2. 7:13Which way do you vote if you're hurt by high drug prices?
Interviewer 0:01 ↗
How come you didn't get a warm welcome?
Mark Cuban 0:04 ↗
They've already given me a warm welcome. If self-insured employers started paying attention to the details of their benefits contract and stopped allowing themselves to get ripped off on basic things, then we literally could change the entire health care system and the cost of care in this country without requiring anything legislatively.
I'm all for single payer. The question is, how do you get from here to there? You have to actually put together a plan, something nobody's ever done.
It's a question of figuring out what it actually costs and how to get there. But when you talk to everybody and you ask, have you brought in Mayo Clinic? Have you brought in Stanford? Have you brought in all the high-end providers who have high cost, the fancy pianos, the artwork, and everything? How are they going to get from where they are today with their cost structure to where you want to go at Medicare rates?
The Democrats want the premium tax credits to come through, right? And I just happened to look it up yesterday. Prior to the removal of premium tax credits, the average deductible was $2,700 for a silver plan. Percentage of people who can afford a $400 emergency cost — you know, let's say 40% of people can't afford an emergency bill of $400. You think they can afford a $2,700 deductible? So, by reinstituting the premium tax credits, all you're doing is funneling more money to the big carriers.
That's it. Now, maybe the good news is more of those carriers will offer ACA plans in more states because there's more money there. Okay, you can make that argument, but the reality is all it is is a revenue plan for the big carriers, which, you know, is not what I think they're trying to accomplish.
The things that we could do that can immediately make things more affordable that nobody is offering is: number one, there's eight states that say if you can buy care or medications for less than your out-of-pocket of your plan, they are required to count that out-of-pocket purchase towards your deductible. Do that nationally. Now all of a sudden, people pay attention and have to realize that if their co-pays or max out-of-pocket are too high, people are going to find other sources. Hopefully Cost Plus Drugs, but it could be anywhere. Could be medical as well.
Number two, any contract that has taxpayer money at all must be published with no redactions. It's funny because all the big carriers, they'll say, well, our pricing is proprietary. You show that pricing to 50 states, 5,000 school districts. You know, there's 250,000 people that see your prices and you're trying to say it's proprietary, but you treat it like Fight Club. You know Fight Club — anybody who talks, the number one rule of Fight Club is you can't talk about Fight Club. The number one rule of health care benefits contracts and pricing is you can't talk about them or you'll get sued by one of the big carriers.
You have to end that so there's truly price discovery, because once you have price discovery, then all of a sudden you can have an efficient market, which means now all of a sudden people can actually shop, things can happen. But as long as you can't see the contracts in addition to seeing the prices, it's not going to work. They're not dumb. The big carriers got to be multi-hundred-billion-dollar companies for a reason. They're not dumb. Right? They know when they have the edge and the angles, and they use it. And so the things that we're seeing from politicians now, you know, it's sloganeering from both sides. Nobody's doing anything to improve the cost of health care.
Let's talk about why we have mostly generics. I want to sell every drug that we're legally allowed to sell. The only reason we don't have every single brand and specialty drug is because the PBMs have gone to the big brand manufacturers and said, 'If you work with CostPlusDrugs.com, we will diminish your positioning on our formulary for your entire portfolio, which could cost you tens, hundreds, millions of dollars, or more.'
Now, why would they care about a little piss-ant company like ours with 70 employees? I'll tell you, because they saw what happened to specialty generics. The minute we started publishing our cost and only had a 15% markup, and our price for imatinib and other, you know, specialty drugs was visible to everybody, the price everywhere dropped like a rock.
There's a study that's coming out where they came to me and they said, 'Look, every single element of health care costs have gone up over the last 30 years, except in 2022 the price of generics started going down because the higher-end generics, things that we were selling for less than everybody else, went down significantly, and everybody had to come closer, match, or at least talk about that they were.' So these big PBMs owned by these big conglomerates were telling the brands that if you work with costplusdrugs.com, we're going to cost you a lot of money. And they'll tell me, 'Mark, we love you. We'd love to work with you, but we can't cut off our nose to spite our face.'
For our manufacturing in Dallas, we took what used to be the size of a football field and shrunk it to about 5,000 square feet. And then we shrunk that 5,000 square feet using robotics and AI down to the size of a tractor-trailer. And we call them pods. And we can daisy-chain those pods, so we have one element of the manufacturing here, the tableting portion here.
And in doing it that way, even by buying the API in this particular case, the ingredients that go into the drug, even by buying those from India or China, wherever the only places we can buy them from are, we can manufacture those drugs in Dallas for less than we buy them from India. Now, I have to qualify by saying we don't go out and buy the cheapest price; we buy the highest quality and try to get the best price. So it's a little bit higher than maybe someone else might pay for it, but we can manufacture at that price in Dallas.
The only thing holding us back in order to do that for the 2,500 drugs, right? We have to pay $365,000 each for what's called an ANDA application, an abbreviated new drug application. $365,000 times 1,000 new drugs is $365 million, which distorts and destroys the economics of producing it less expensively in the US. So we're talking to the FDA to try to get approval. And you know, no disrespect to the FDA because they're working hard to try to figure it out, because they want to reshore manufacturing, but we can. When we can do it not only for, you know, generics, but we can do it pretty much for anything.
You are getting ripped off, but you keep on doing business with the people who rip you off. And literally...
Interviewer 7:13 ↗
Thinking about the midterm elections, so we've heard a lot about grocery, gas prices as being voting issues. Do you think that drug pricing is a voting question this year? And if so, who would you vote for? Which way do you vote if you're hurt by high drug prices?
Mark Cuban 7:37 ↗
I mean, I'm not going to pick one candidate over the other because none of them know what they're doing. Seriously.

4 more exchanges in this transcript

Sign in free to read the rest of this interview. No card required.

Sign in to read the full transcript

Cite this transcript

APA, MLA, BibTeX
APA

Cuban, M. (2026, October 26). "I'm Not a Doomer!" Mark Cuban Explains Why AI Hackers Can Be Defeated With AI Defense | AC1B [Interview transcript]. DRM News. CEOInterviews.AI. https://ceointerviews.ai/interview/3178603/

MLA

Mark Cuban. ""I'm Not a Doomer!" Mark Cuban Explains Why AI Hackers Can Be Defeated With AI Defense | AC1B." DRM News, 26 Oct. 2026. Transcript, CEOInterviews.AI, https://ceointerviews.ai/interview/3178603/.

BibTeX
@misc{cuban2026_3178603,
  author       = {Mark Cuban},
  title        = {"I'm Not a Doomer!" Mark Cuban Explains Why AI Hackers Can Be Defeated With AI Defense | AC1B},
  howpublished = {Interview transcript, DRM News. CEOInterviews.AI},
  year         = {2026},
  month        = {oct},
  url          = {https://ceointerviews.ai/interview/3178603/},
  note         = {Speaker-attributed transcript with timestamps}
}